Trial Profile
A Phase Ib Trial of BYL719 (an alpha-Specific PI3K Inhibitor) in Combination With Endocrine Therapy in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2023
Price :
$35
*
At a glance
- Drugs Alpelisib (Primary) ; Letrozole
- Indications Advanced breast cancer; Carcinoma
- Focus Adverse reactions
- Sponsors Novartis
- 04 Dec 2023 Planned End Date changed from 1 Oct 2023 to 31 May 2024.
- 14 Oct 2022 Planned End Date changed from 1 Aug 2022 to 1 Oct 2023.
- 05 Apr 2022 Planned End Date changed from 1 Feb 2022 to 1 Aug 2022.